Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mindset Pharma Inc (OP: MSSTF ) N/A UNCHANGED Last Price Updated: 3:55 PM EDT, Oct 24, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Mindset Pharma Inc < Previous 1 2 3 4 Next > Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic September 18, 2023 Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic... Via Benzinga Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More September 05, 2023 Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Via Benzinga Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions August 31, 2023 Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka... Via Benzinga Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application July 18, 2023 As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also... Via Benzinga Reunion Neuroscience On The Brink Of Going Private With Final Court Approval July 17, 2023 Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution... Via Benzinga Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More July 04, 2023 World's Largest Psychedelics Conference Boasts 12K Attendees Via Benzinga Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3 June 29, 2023 Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the... Via Benzinga UK Greenlights Phase 2 Clinical Trial On Mindset Pharma's Psilocin Drug For Major Depression June 27, 2023 Drug discovery company Mindset Pharma (OTCQB: MSSTF) received approval from the U.K. Via Benzinga Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More May 01, 2023 Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued Via Benzinga This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection April 26, 2023 Numerous biopharma companies are working on enhancing first-generation or “classical” psychedelics. They're tuning down the side effects, and protecting their findings along the way. Via Benzinga New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market April 25, 2023 Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual... Via Benzinga Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More March 20, 2023 Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered Via Benzinga Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court March 14, 2023 Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey. Via Benzinga Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More March 13, 2023 Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial Via Benzinga Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla March 06, 2023 The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia. Via Benzinga Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded February 03, 2023 Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders Via Benzinga Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More January 25, 2023 Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? Via Benzinga Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News January 21, 2023 Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for... Via Benzinga Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More November 21, 2022 Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy Via Benzinga These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details November 16, 2022 Next-gen psychedelics producers Mindset Pharma Inc. (OTCQB: MSSTF) and PharmAla Biotech Holdings Inc. Via Benzinga EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance November 07, 2022 (Part four of a four-part series) See previous stories in this series: Via Benzinga European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed October 11, 2022 UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used... Via Benzinga Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More October 07, 2022 Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy Via Benzinga Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials October 07, 2022 Biopharma R&D company Mindset Pharma Inc. Via Benzinga Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family September 27, 2022 Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc. Via Benzinga Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close? September 14, 2022 Biotech drug discovery firm Mindset Pharma Inc. Via Benzinga Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries September 07, 2022 Psychedelics R&D company Mindset Pharma (OTCQB: MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of... Via Benzinga Psychedelic Stock Gainers And Losers From September 7, 2022 September 07, 2022 GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.66% at $1.12 Via Benzinga Most, But Not All, Psychedelics Companies Have Sufficient Liquidity September 06, 2022 The Chart represents the liquidity positions of the 21 Psychedelic sector companies in the Viridian Value Tracker database. Via Benzinga Small Pharma, Revive Therapeutics Among Top Psychedelic Movers Of Today September 02, 2022 GAINERS: Small Pharma (OTC:DMTTF) shares closed up 6.41% at $0.29 Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
